Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, March 2001, p. 913-916, Vol. 45, No. 3
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.3.913-916.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Glutathione-Induced Conversion of Pentavalent
Antimony to Trivalent Antimony in Meglumine Antimoniate
Frédéric
Frézard,1,*
Cynthia
Demicheli,2
Claúdio S.
Ferreira,1 and
Michelle
A. P.
Costa1
Departamento de Fisiologia e
Biofísica, Instituto de Ciências
Biológicas,1 and Departamento de
Química, Instituto de Ciências
Exatas,2 Universidade Federal de Minas Gerais,
31270-901 Belo Horizonte, MG, Brazil
Received 5 June 2000/Returned for modification 21 October
2000/Accepted 23 December 2000
 |
ABSTRACT |
The standard treatment of human leishmaniases involves the use of
pentavalent antimony [Sb(V)] compounds, including meglumine antimoniate. The mode of action of these compounds has not been fully
elucidated. The possibility that Sb(III) is involved has been
suggested; however, the biomolecule that may induce the conversion of
Sb(V) to Sb(III) has not yet been identified. In the present study, we
investigated both the ability of reduced glutathione (GSH) to promote
the reduction of Sb(V) into Sb(III) in meglumine antimoniate and the
effects of pH and temperature on this transformation. GSH did promote
the reduction of Sb(V) into Sb(III) in a dose-dependent manner. When
GSH and meglumine antimoniate were incubated together at a GSH/Sb molar
ratio superior or equal to 5:1, all antimony was encountered in the
reduced form, indicating a stoichiometry of 5:1 between GSH and Sb(V)
in the reaction. The reaction between Sb(V) and GSH was favored at an
acidic pH (pH 5) and an elevated temperature (37°C), conditions found
within the phagolysosome, in which Leishmania resides.
For instance, about 30% of the Sb(V) (concentration, 2mM) was
converted to Sb(III) following incubation for 3 days with 10 mM GSH at
pH 5 and 37°C. Our data support the hypothesis that Sb(V) would be
converted by GSH, or a related thiol compound, to more toxic Sb(III) in
the phagolysosome of macrophages.
 |
INTRODUCTION |
The leishmaniases are a group of
diseases produced by invasion of the reticuloendothelial system of a
vertebrate host by a parasite of the genus Leishmania. This
parasite is found as a motile promastigote in the sandfly; it
transforms into an amastigote when engulfed by host macrophages and
resides in the acidic environment of secondary lysosomes
(1). These diseases are a significant cause of morbidity
and mortality in several countries of the world. The treatment of
choice for all forms of leishmaniasis depends on pentavalent antimony
[Sb(V)]-containing drugs such as meglumine antimoniate (Glucantime)
and sodium stibogluconate (Pentostam). Despite the clinical use of
these antileishmanial agents for over half a century, their mechanism
of action and the basis for their selective toxicity remain unknown.
The hypothesis that Sb(V) acts as a prodrug that is converted to the
more toxic trivalent antimony [Sb(III)] at or near the site of action
was first suggested by Goodwin and Page (9), after they
observed that a host organism can reduce Sb(V) into Sb(III). Recently,
hydride generation-atomic absorption spectrometry analysis of serum and
urine from patients treated with meglumine antimoniate revealed that 15 to 25% of serum antimony and 50% of urine antimony were trivalent
(3, 15). This hypothesis was further supported by the
observations that Sb(III) is more toxic than Sb(V) against both
parasite stages of different Leishmania species (13,
19, 21) and that mutants of Leishmania infantum
amastigotes selected for resistance to Sb(III) were cross-resistant to
Sb(V) inside monocytes (22).
Recently, however, Ephros et al. (6) showed that
axenically grown amastigotes were highly sensitive to Sb(V) and
suggested that Sb(V) is directly and specifically toxic to amastigotes. Until now, the biomolecule that promotes the reduction of Sb(V) into
Sb(III) and the location where this reaction occurs have not been
identified. Reduced glutathione (GSH) is a likely candidate as a
reducing agent for Sb(V). First, GSH is the most prevalent cellular
thiol (12), present within the cytosol at high (2 to 10 mM) concentrations. Secondly, GSH was previously found to be oxidized
in the presence of arsenate [As(V)] (20). This reaction may also occur with Sb(V), instead of As(V), since antimony lies directly below arsenic in the periodic table.
In the present study, we investigated the ability of GSH to promote the
reduction of Sb(V) into Sb(III) in meglumine antimoniate, as well as
the effects of pH and temperature on this transformation. The results
obtained led us to propose a model for the mechanism of action of
antimonials and the basis for their selective toxicity.
 |
MATERIALS AND METHODS |
Materials.
GSH (Sigma Chemical Co., St. Louis, Mo.)
was used as supplied and stored at 4°C. N-methyl
glucamine, bromopyrogallol red (BPR), and potassium antimony tartrate
were obtained from Aldrich Chemical Co. (Milwaukee, Wis). Commercial
preparations of meglumine antimoniate (Glucantime, also known as RP
2168) were obtained from Rhône-Poulenc SA (Paris, France) in
powder form and from Rhodia Farma LTDA (São Paulo, Brazil) as a
solution in ampoule. All other reagents were of at least reagent grade.
Double-distilled, deionized water was used throughout the experiments.
Drug preparation.
Meglumine antimoniate was synthesized as
previously described (4) from equimolar amounts of
N-methyl glucamine and oxyhydrated pentavalent antimony. The
resulting product contained approximately 30% antimony by weight, as
determined by atomic absorption spectroscopy. This product was used
throughout the experiments.
Study of reduction of Sb(V) in the presence of GSH.
To
assess the effect of the GSH/Sb(V) ratio on the production of Sb(III),
different tubes were prepared with aqueous solutions of meglumine
antimoniate and GSH at different molar ratios. The Sb(V) concentration
was kept at 10 mM, and the GSH concentration varied from 0 to 100 mM.
The pH was adjusted to 3.5 when necessary. All solutions were
deoxygenated by bubbling with argon, and the tubes were flushed with
argon before being closed to protect GSH from air oxidation. Samples
were kept at 25°C and analyzed for Sb(III) content 7 days later.
To assess the effect of the pH level on the production of Sb(III),
different solutions containing meglumine antimoniate (Sb concentration,
10 mM) and 50 mM GSH were prepared, with the pH level varying from 2 to
8. The pH was adjusted by adding small aliquots of either potassium
hydroxide- or hydrogen chloride-concentrated solutions. Samples were
kept under an argon atmosphere at 25°C and analyzed for Sb(III)
content after 24 h.
To determine the kinetics of antimony reduction in model conditions of
physiological state, solutions containing meglumine
antimoniate
(antimony concentration, 2 mM) and 10 mM GSH were
prepared in 0.15 M
KCl at pH 5 or 7.2 and at 25 or 37°C. The amount
of Sb(III) was
determined after different times of
incubation.
Determination of Sb(III).
The procedure used to determine
Sb(III) was described in detail previously (18). It is
based on the specific interaction of Sb(III) with the chromogen BPR.
The absorbance of BPR at 560 nm decreases proportionally to the amount
of Sb(III) in the analyte solution, as a consequence of the formation
of the 1:1 BPR-Sb(III) complex. Briefly, 2.5 ml of analyte solution was
prepared from 0.5 ml of 0.1 M phosphate, 0.05 ml of 5% (wt/vol)
tartrate, 0.25 ml of 350 µM BPR solution in 1:1 (vol/vol)
water-ethanol, and 1.7 ml of water. The pH was then adjusted to 6.8. The absorbance was registered at 560 nm before
(A0) and after (Am) the
addition of 5 to 25 µl of the sample to be analyzed, so as to obtain
a final antimony concentration of 20 µM. For each experiment, a calibration curve was established, using potassium antimony tartrate as
the source of Sb(III), by plotting the difference in absorbance (A0
Am) as a
function of Sb(III) concentration. We checked that neither Sb(V) nor
GSH interfered with the colorimetric test. Moreover, we observed that
the presence of GSH in the analyte solution did not interfere with the
formation of the BPR-Sb(III) complex.
 |
RESULTS |
Reduction of Sb(V) into Sb(III) as a function of GSH/Sb(V)
ratio.
The fraction of Sb(III) present in freshly prepared
meglumine antimoniate (4) as well as in commercial
meglumine antimoniate was found to be less than 0.2% of the total
antimony, indicating that antimony was initially in the pentavalent
form. Meglumine antimoniate was incubated (Sb concentration, 10 mM) in
the presence of GSH at a concentration varying from 10 mM to 100 mM at
pH 3.5. After a week of incubation at 25°C in an argon atmosphere,
the samples were analyzed for Sb(III) content. The results, displayed in Fig. 1, show that GSH induced the
reduction of Sb(V) in a dose-dependent manner, indicating that an
oxidation-reduction reaction between Sb(V) and GSH occurred. When GSH
was absent from the incubation medium, the amount of antimony reduced
in the same period of time was insignificant. It is noteworthy that,
from a GSH/Sb ratio of 5:1, all antimony was encountered in the reduced
form, indicating a stoichiometry of 5:1 between GSH and Sb(V) in the
reaction. Cysteine, in the same experimental conditions, was also found to promote the reduction of Sb(V) into Sb(III) (data not shown); however, it was not possible to perform quantitative analysis due to
the appearance of a precipitate in the incubation medium.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 1.
Level of Sb(III) produced in aqueous solutions of
meglumine antimoniate and GSH, as a function of the GSH/Sb(V) molar
ratio. The antimony concentration was maintained at 10 mM. Solutions
were kept at 25°C for 7 days. The results are expressed as means ± standard deviations (error bars) (n = 3).
|
|
Reduction of Sb(V) into Sb(III) as a function of pH.
Meglumine antimoniate was incubated (Sb concentration, 10 mM) with
50 mM GSH for 24 h at 25°C in an argon atmosphere, at a pH varying
from 2 to 8. The results displayed in Fig.
2 indicate that the level of Sb(III)
produced in these conditions decreased when the pH increased from 3 to
8. The reaction between Sb(V) and GSH at pH 7 was found to procced more
than five times as slowly as that at pH 3.

View larger version (9K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of pH on the concentration of Sb(III) produced in
an aqueous solution of meglumine antimoniate and GSH. Solutions were
kept at 25°C for 24 h. Initial Sb(V) concentration, 10 mM;
initial GSH concentration, 50 mM. The results are expressed as
means ± standard deviations (error bars) (n = 3).
|
|
Kinetics of antimony reduction in model conditions of physiological
state.
To get insight into the physiopharmacological significance
of this reaction, we performed evaluations using the different conditions of pH and temperature to which Sb(V) is expected to be
exposed while migrating to its site of action. Hence, pH 7.2 would
mimic the pH of external medium and that of cytosol, whereas pH 5 would
mimic the pH of the phagolysosome. Moreover, a GSH concentration of 10 mM was chosen, so as to be close to the average cellular concentration,
and the Sb(V) concentration was kept at a lower value (2 mM). Finally,
the reaction was performed in a solution of 0.15 M KCl in an atmosphere
of either argon or air. Figure 3 displays
the kinetics of reduction of Sb(V) in an argon atmosphere under
different conditions of temperature and pH. The results clearly
established that the reaction occurred at pH 5 (and 37°C); however,
no significant amount of Sb(III) was detected at pH 7.2. Temperature
was also found to have a strong influence on the rate of reduction.
About 30% of the Sb(V) was converted to Sb(III) at 37°C following a
3-day incubation at pH 5, but less than 4% was converted to Sb(III)
when the reaction was performed at 25°C. Moreover, no significant
increase of the amount of Sb(III) was observed between day 3 and day 7 of incubation at 25°C. The same behavior was observed when
samples were kept under an atmosphere of air instead of argon, and the
results did not differ significantly (data not shown).

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 3.
Kinetics of production of Sb(III) in aqueous solutions
of meglumine antimoniate and GSH in different conditions of pH and
temperature, as follows: pH 7.2 at 37°C ( ), pH 5 at 37°C ( ),
and pH 5 at 25°C ( ). Initial Sb(V) concentration, 2 mM; initial
GSH concentration, 10 mM. Solutions were maintained in an argon
atmosphere. The results are expressed as means ± standard
deviations (error bars) (n = 3).
|
|
 |
DISCUSSION |
Our data clearly demonstrate that GSH promotes the
reduction of Sb(V) to Sb(III) and that the oxidation-reduction reaction is greatly favored at an acidic pH level and an elevated temperature. It is noteworthy that the stoichiometry of 1:5 could be determined in
the reaction between Sb(V) and GSH. A similar reaction was previously
reported in the case of arsenate [As(V)] and GSH (20), and the stoichiometry of 1:5 was attributed to the formation of As(GS)3 complex between As(III) and GSH. By analogy, and
considering that Sb and As have very similar chemical properties, the
formation of an Sb(GS)3 complex can also be proposed. This
interpretation is also supported by a recent study that established the
formation of Sb(GS)3 from Sb(III) and GSH
(23). Thus, in order to reduce one equivalent of Sb(V),
five equivalents of GSH are needed, including three equivalents that
would form the Sb(GS)3 complex.
Such a conversion was previously suggested by Dey et al.
(5), following the observation that sodium stibogluconate
became an effective inhibitor of As(GS)3 transport after an
overnight incubation with GSH. Our findings, however, constitute the
first direct evidence for the occurrence of this oxidation-reduction reaction.
It can be assumed that (i) the antimony complex must first dissociate
to allow for Sb(V) reduction, (ii) the main soluble forms of Sb(V) and
Sb(III) in the pH range of 2 to 8 are SbO3
and HSbO2, respectively (16), and (iii) the
half-reaction for antimony reduction occurs as follows (see reference
16):
|
(1)
|
Based on these assumptions, the following oxidation-reduction
reaction can be proposed:
|
(2)
|
where GS-SG is the oxidized form of glutathione. According to
Pitman et al. (
16), the redox potential for half-reaction
1 at 25°C can be expressed by the equation
EHSbO2 = 0.678

0.0886(pH)
+ 0.0295{log
([SbO
3]/[HSbO
2])} (here, as below, pH
serves as a
variable representing an unspecified pH level). On the
other hand,
the redox potential for the glutathione reduction
half-reaction
at 25°C can be expressed by the equation
E°
GSH =
E°
GSH 
0.059(pH)
+ 0.0295{log
[(concentration of GS-SG)/(concentration of GSH)
2]}.
Since the apparent standard redox potential for the glutathione
reduction half-reaction at pH 7 and 25°C
(
E°'
GSH) is

0.240 V
(
2), one
can deduce the value of the standard redox potential
as follows:
E°
GSH = 0.173 V. Taking this data into
consideration,
the apparent standard redox potential for reaction 2 can
be expressed
as a function of the pH at 25°C by the following
equation:
According to this equation, in the range of pH levels studied, the
reaction equilibrium is expected to be almost completely
displaced
towards the formation of Sb(III). Therefore, the strong
dependence of
Sb(III) production on the pH level cannot be explained
on the basis of
thermodynamics, but rather on the basis of kinetic
and/or mechanistic
considerations. The formation of the Sb(GS)
3 complex may be
described by the following reaction:
|
(3)
|
Therefore, from reactions 2 and 3, the following general reaction
can be proposed:
According to our results, the conversion of Sb(V) to Sb(III)
should not occur in the host cell cytosol due to its neutral
pH, even
if this compartment contains a high concentration of
GSH. On the other
hand, antimony reduction may occur in the macrophage
acidic organelles,
such as lysosomes and endosomes, and also in
the parasitophorous
vacuole, whose pH lies between 4.7 and 5.2,
in which
Leishmania resides (
1). However, GSH, or
another related
thiol compound, should be present at a high
concentration in these
organelles so that the reaction can occur. This
seems to be the
case because high concentrations of reduced thiol were
found to
be required for the reduction of protein disulfide bonds in
the
course of antigen processing (
10). However, it is not
clear
which thiol compound (cysteine, cysteinyl-glycine, or GSH) is
the
most abundant in these organelles (
8,
11).
On the basis of our data, the following model can be proposed for the
mechanism of action of antimonials. As a first step, Sb(V) may reach
the parasitophorous vacuole, either by drug diffusion across the plasma
and lysosome membranes of macrophage or via the endocytic pathway,
assuming, for instance, the transfer of Sb(V) from its original ligand
to some carbohydrates of the host cell surface. As a second step, Sb(V)
would be reduced into Sb(III) in the presence of thiols coming from the
host cell or even from the parasite. As a third step, Sb(III) would
accumulate inside the phagolysosome, penetrate inside the parasite, and
interact with key leishmanial sulfhydryl groups, resulting in parasite death. Given that after a short exposure to antimonial drugs
macrophages were found to retain antimony for several days
(19), one can expect that Sb(V) reduction at pH 5 and
37°C is fast enough to generate a sufficient amount of Sb(III) to
kill the parasite. It is noteworthy that, according to this model, host
cells would be relatively protected from the toxic effects of Sb(III),
especially if Sb(V) enters the host cells by phagocytosis, since its
intracellular location would be restricted mainly to the
lysosome-endosome compartments.
As another implication, our data may explain why promastigotes,
contrary to intracellular amastigotes, are insensitive to Sb(V).
Indeed, the conditions of pH (neutral) and temperature (25°C) usually
employed to assess the activity of antileishmanial agents against
promastigotes may not favor the reduction of Sb(V) into Sb(III).
On the other hand, our model for the mechanism of action of antimonials
seems contradictory to the recent conclusion of Ephros et al.
(6) that Sb(V) would enter the parasite cells and
subsequently exert its antileishmanial effect. This conclusion was
based on the observation that axenic amastigotes, derived from
promastigotes differentiated at an acidic pH level (pH 5.5) and
elevated temperature (37°C), were highly sensitive to Sb(V). In order
to rule out the possibility that Sb(V) was reduced to Sb(III) by the
growth medium, the authors showed that neither acidic pH nor elevated
temperature alone resulted in increased toxicity of Sb(V) to
promastigotes. However, it was not possible to assess the effects of
the combination of the acidic pH and the elevated temperature. The lack
of significant reduction of Sb(V) either at pH 5 (and 25°C) or at
37°C (and pH 7.2) reported in our study is in good agreement with
their report. However, we did observe a significant level of Sb(V)
reduction when incubating meglumine antimoniate and GSH at pH 5 and
37°C, which are precisely the conditions used to promote the
transformation of promastigotes to axenic amastigotes. Therefore, the
conversion of Sb(V) into Sb(III) in the conditions used by these
investigators cannot be ruled out. The reduced thiol required for the
reduction of Sb(V) into Sb(III) may have come from the growth medium
used in this assay or may have been produced and excreted by the
parasites in the course of their differentiation. Nevertheless,
alternative models, such as (i) the catalysis of the reaction by a
reductase such as that recently identified for Saccharomyces
cerevisiae, which promoted the reduction of arsenate to arsenite
(14); (ii) the reduction of Sb(V) by trypanothione in the
parasite cytosol (7); and (iii) the reduction of Sb(V)
within acidic compartments of the parasite (17), cannot be excluded.
In conclusion, we demonstrated that GSH promotes the reduction of Sb(V)
to Sb(III) and characterized the oxidation-reduction reaction. We
observed that this reaction is much faster at an acidic pH level than
at a neutral pH level, suggesting that GSH and/or related thiol
compounds are involved in the reduction of Sb(V) in vivo in the
phagolysosome of macrophages.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from CNPq (521010/97-7),
FAPEMIG (CBS2418/96), and PRONEX (Brazil).
We thank Jean Michel Pernaut for his helpful suggestions during the
preparation of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Departamento de
Fisiologia e Biofísica, Instituto de Ciências
Biológicas, Universidade Federal de Minas Gerais, Av.
Antônio Carlos 6627, Pampulha, 31270-901 Belo Horizonte, MG,
Brazil. Phone: (55) 313-4992940. Fax: (55) 313-4992924. E-mail:
frezard{at}mono.icb.ufmg.br.
 |
REFERENCES |
| 1.
|
Alexander, J., and D. G. Russel.
1992.
The interaction of Leishmania species with macrophages.
Adv. Parasitol.
31:175-254[Medline].
|
| 2.
|
Aslung, F.,
K. D. Berndt, and A. Holmgren.
1997.
Redox potentials of glutaredoxins and other thiol-disulfide oxidoreductases of the thioredoxin superfamily determined by direct protein-protein redox equilibria.
J. Biol. Chem.
272:30780-30786[Abstract/Free Full Text].
|
| 3.
|
Burguera, J. L.,
M. Burguera,
Y. Petit de Pena,
A. Lugo, and N. Anez.
1993.
Selective determination of antimony(III) and antimony(V) in serum and urine and of total antimony in skin biopsies of patients with cutaneous leishmaniasis treated with meglumine antimoniate.
Trace Elem. Med.
10:66-70.
|
| 4.
|
Demicheli, C.,
T. L. de Figueiredo,
S. Carvalho,
R. D. Sinesterra,
J. C. Lopes, and F. Frézard.
1999.
Physico-chemical characterization of meglumine antimoniate.
Biometals
12:63-66[CrossRef][Medline].
|
| 5.
|
Dey, S.,
M. Ouellette,
J. Lightbody,
B. Papadopoulou, and B. P. Rosen.
1996.
An ATP-dependent As(III)-glutathione transport system in membrane vesicles of Leishmania tarentolae.
Proc. Natl. Acad. Sci. USA
93:2192-2197[Abstract/Free Full Text].
|
| 6.
|
Ephros, M.,
A. Binun,
P. Shaked,
E. Waldman, and D. Zilberstein.
1999.
Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.
Antimicrob. Agents Chemother.
43:278-282[Abstract/Free Full Text].
|
| 7.
|
Fairlamb, A. H., and A. Cerami.
1992.
Metabolism and functions of trypanothione in kinetoplastida.
Annu. Rev. Microbiol.
46:695-729[CrossRef][Medline].
|
| 8.
|
Gainey, D.,
S. Short, and K. L. McCoy.
1996.
Intracellular location of cysteine transport activity correlates with productive processing of antigen disulfide.
J. Cell. Physiol.
168:248-254[CrossRef][Medline].
|
| 9.
|
Goodwin, L. C., and J. E. Page.
1943.
A study of the excretion of organic antimonials using a polarographic procedure.
Biochem. J.
22:236-240.
|
| 10.
|
Lloyd, J. B.
1986.
Disulphide reduction in lysosomes.
Biochem. J.
237:271-272[Medline].
|
| 11.
|
Mego, J. L.
1985.
Stimulation of intralysosomal proteolysis by cysteinyl-glycine, a product of the action of gamma-glutamyl transpeptidase on glutathione.
Biochim. Biophys. Acta
841:139-144[Medline].
|
| 12.
|
Meister, A.
1988.
Glutathione metabolism and its selective modification.
J. Biol. Chem.
263:17205-17208[Free Full Text].
|
| 13.
|
Mottram, J. C., and G. H. Coombs.
1985.
Leishmania mexicana: enzyme activities of amastigotes and promastigotes and their inhibition by antimonials and arsenicals.
Exp. Parasitol.
59:151-160[CrossRef][Medline].
|
| 14.
|
Mukhopadhyay, R., and B. P. Rosen.
1998.
Saccharomyces cerevisiae ACR2 gene encodes an arsenate reductase.
FEMS Microbiol. Lett.
168:127-136[CrossRef][Medline].
|
| 15.
|
Petit de Pena, Y.,
M. Gallignani,
M. Burguera,
J. L. Burguera,
N. Anez, and Y. Lugo.
1990.
Selective determination of antimony(III) and antimony(V) in blood serum and urine by hydride generation and atomic absorption spectrometry.
J. Braz. Chem. Soc.
1:72-75.
|
| 16.
|
Pitman, A. L.,
M. Pourbaix, and N. de Zoubov.
1957.
Potential-pH diagram of the antimony-water system. Its applications to properties of the metal, its compounds, its corrosion, and antimony electrodes.
J. Electrochem. Soc.
104:594-600.
|
| 17.
|
Rabinovitch, M.
1989.
Leishmanicidal activity of amino acid and peptide esters.
Parasitol. Today
5:299-301.
|
| 18.
|
Rath, S.,
W. F. Jardim, and J. G. Dórea.
1997.
A simple spectrophotometric procedure for the determination of antimony(III) and (V) in antileishmanial drugs.
Fresenius' J. Anal. Chem.
358:548-550[CrossRef].
|
| 19.
|
Roberts, W. L.,
J. D. Berman, and P. M. Rainey.
1995.
In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.
Antimicrob. Agents Chemother.
39:1234-1239[Abstract].
|
| 20.
|
Scott, N.,
K. M. Hatlelid,
N. E. MacKenzie, and D. E. Carter.
1993.
Reactions of arsenic(III) and arsenic(V) species with glutathione.
Chem. Res. Toxicol.
6:102-106[CrossRef][Medline].
|
| 21.
|
Sereno, D., and J. L. Lemesre.
1997.
Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents.
Antimicrob. Agents Chemother.
41:972-976[Abstract].
|
| 22.
|
Sereno, D.,
M. Cavaleyra,
K. Zemzoumi,
S. Maquaire,
A. Ouaissi, and J. L. Lemesre.
1998.
Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action.
Antimicrob. Agents Chemother.
42:3097-3102[Abstract/Free Full Text].
|
| 23.
|
Sun, H.,
S. C. Yan, and W. S. Cheng.
2000.
Interaction of antimony tartrate with the tripeptide glutathione.
Eur. J. Biochem.
267:5450-5457[Medline].
|
Antimicrobial Agents and Chemotherapy, March 2001, p. 913-916, Vol. 45, No. 3
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.3.913-916.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Wyllie, S., Vickers, T. J., Fairlamb, A. H.
(2008). Roles of Trypanothione S-Transferase and Tryparedoxin Peroxidase in Resistance to Antimonials. Antimicrob. Agents Chemother.
52: 1359-1365
[Abstract]
[Full Text]
-
Barroso, P. A., Marco, J. D., Calvopina, M., Kato, H., Korenaga, M., Hashiguchi, Y.
(2007). A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate. J Antimicrob Chemother
59: 1123-1129
[Abstract]
[Full Text]
-
Ashutosh, , Sundar, S., Goyal, N.
(2007). Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol
56: 143-153
[Abstract]
[Full Text]
-
Kuryshev, Y. A., Wang, L., Wible, B. A., Wan, X., Ficker, E.
(2006). Antimony-Based Antileishmanial Compounds Prolong the Cardiac Action Potential by an Increase in Cardiac Calcium Currents. Mol. Pharmacol.
69: 1216-1225
[Abstract]
[Full Text]
-
Croft, S. L., Sundar, S., Fairlamb, A. H.
(2006). Drug Resistance in Leishmaniasis. Clin. Microbiol. Rev.
19: 111-126
[Abstract]
[Full Text]
-
Decuypere, S., Rijal, S., Yardley, V., De Doncker, S., Laurent, T., Khanal, B., Chappuis, F., Dujardin, J.-C.
(2005). Gene Expression Analysis of the Mechanism of Natural Sb(V) Resistance in Leishmania donovani Isolates from Nepal. Antimicrob. Agents Chemother.
49: 4616-4621
[Abstract]
[Full Text]
-
Holzmuller, P., Sereno, D., Lemesre, J.-L.
(2005). Lower Nitric Oxide Susceptibility of Trivalent Antimony-Resistant Amastigotes of Leishmania infantum. Antimicrob. Agents Chemother.
49: 4406-4409
[Abstract]
[Full Text]
-
Wyllie, S., Cunningham, M. L., Fairlamb, A. H.
(2004). Dual Action of Antimonial Drugs on Thiol Redox Metabolism in the Human Pathogen Leishmania donovani. J. Biol. Chem.
279: 39925-39932
[Abstract]
[Full Text]
-
Sudhandiran, G., Shaha, C.
(2003). Antimonial-induced Increase in Intracellular Ca2+ through Non-selective Cation Channels in the Host and the Parasite Is Responsible for Apoptosis of Intracellular Leishmania donovani Amastigotes. J. Biol. Chem.
278: 25120-25132
[Abstract]
[Full Text]
-
Carter, K. C., Sundar, S., Spickett, C., Pereira, O. C., Mullen, A. B.
(2003). The In Vivo Susceptibility of Leishmania donovani to Sodium Stibogluconate Is Drug Specific and Can Be Reversed by Inhibiting Glutathione Biosynthesis. Antimicrob. Agents Chemother.
47: 1529-1535
[Abstract]
[Full Text]